couter

MDCXMedicus Pharma Ltd. Common Stock

Jan 31, 2027 — Potential Nasdaq minimum bid price compliance decision / reverse split
Chart by TradingView

The schedule

  • Sun31Jan

    If Medicus Pharma remains around $0.40, Nasdaq could require a plan to regain $1.00 bid compliance, potentially via a reverse split or other actions, with a decision point in early 2027.

  • Mon8Feb
  • Wed31Mar

    The 2026 10-K filing around $0.40 will include audited financials and any going-concern language, clarifying long-term viability and capital needs.

  • Mon10May
  • Mon9Aug

Past

  • Mon9Nov
  • Sat15Aug

    Actual outcome: Bear · $0.16 at outcome

    Medicus Pharma addressed its cash runway needs by raising approximately $40 million through equity and debt financing in the first half of 2026, alongside reporting FDA authorization to proceed with its SkinJect study. Despite removing the immediate financing overhang and demonstrating clinical progress, the stock reaction was muted, declining just 3% and resulting in a mixed outcome.

    Given ongoing losses and limited cash, Medicus Pharma is likely to pursue an equity financing around $0.40 within the next 12 months to fund clinical development.

  • Mon10Aug

    Actual outcome: Bear · $0.26 at outcome

    Medicus Pharma reported Q2 2026 financial results, meeting EPS estimates exactly at -$0.43, and highlighted clinical progress across its SkinJect and Teverelix programs. The company also noted it had raised approximately $40 million through equity and debt financing in the first half of the year. Despite meeting earnings expectations and advancing its pipeline, the stock fell 12.9% and dropped well below the bear floor, as the clinical updates and recent capital raise failed to attract buying interest.